HemaCare Corporation

01/13/2022

Listen in >> Donors: The Unsung Heroes Advancing Science, a Vital Science podcast - featuring HemaCare (a Charles River company) discussing the challenges of recruiting cellular product donors during the pandemic, why donors donate, and the increasingly important role of donation in today’s pharmaceutical landscape: https://bit.ly/3nntHwk

01/11/2022

Researchers discovered that the immune system can re-engage to destroy tumors after combining chemotherapy and immunotherapy. Learn more here >> https://bit.ly/33sXkFH

# immunotherapy

By combining chemotherapy and immunotherapy, researchers found that mices’ immune systems re-engaged to destroy their tumors. Learn more here!

11/10/2021

Join Us >> GEN Webinar: Addressing the Challenges of Scaling Cell Therapies – November 18th, 2021. Dr. Matthew Hewitt and Dr. Kimberly Negrin—experts in the field of human-derived biological products and manufacturing—will explore these distinct challenges and strategies to mitigate them. Register Today >> https://bit.ly/3H8Zd9V

In this GEN webinar, Dr. Matthew Hewitt and Dr. Kimberly Negrin—experts in the field of human-derived biological products and manufacturing—will explore these distinct challenges and strategies to mitigate them. From the sheer volume of donors necessary to support cell therapy programs and the b...

11/03/2021

Scientists in Japan have created a new tool to study how cells hide in the body, making it easier to create new cancer cells after treatment. Learn more here: https://bit.ly/3CFjEsr

The risk of cancer returning after treatment is unpredictable, but now scientists in Japan have come up with a new tool to study cancerous stem cells. Learn more here...

10/23/2021

NEW >> We have the solutions you need to investigate the COVID-19 immune response. The research community is urgently working to unravel the immune response mysteries behind the deadly pathology of the SARS-CoV-2 virus to successfully stop it in its tracks.

At HemaCare, we support these research efforts by offering a comprehensive portfolio of COVID-19 immune cell products, which include:
>> Vaccinated Samples (time series)
>> Convalescent Biospecimens
>> Antigen-specific T-cells

These tools are necessary to investigate this deadly disease pathology and ensure success when developing COVID-19 preventative measures & therapeutic interventions. Check out our COVID-19 immune cell products today >> https://bit.ly/3ptDsuN

10/07/2021

Join us at the Cell & Gene Meeting on the Mesa virtual conference: Jordan Hunter, Product Manager, will be presenting on behalf of HemaCare (a Charles River family of companies). October 12th – 14th (livestream), October 19th – 20th (virtual partnering). Register today! >> https://bit.ly/3FuL0Ds

10/06/2021

HemaCare’s T-cells are aiding in cancer immunotherapy research for the Cell and Gene Therapy Catapult in the UK. Learn more about this study and how HemaCare’s CD3+ T-cells were used: https://bit.ly/3AcAqgs

HemaCare's T Cells are aiding in the study for cell therapy...

09/29/2021

An independent publication cites the use of HemaCare-sourced PBMCs as starting material for an assay designed to screen for factors that enhance anti-tumor cytotoxic T cell activity.
Read more about it>> https://bit.ly/39QlFF6

Enhancing anti-tumor T cell function...

09/23/2021

In Germany, a vaccine designed to target brain tumors has passed Phase I human trials and will move on to Phase II. Learn more about how this vaccine impacts the immune system of patients with brain cancer: https://bit.ly/2Zovto0

In Germany, a Phase I human trial for a brain cancer vaccine has passed and will move onto Phase II. Learn more about this study with HemaCare.

09/15/2021

Researchers are seeing positive results when fighting systemic fungal infections by using CAR-T cell therapy. Learn how this immunotherapy, typically used in cancer treatments, has been adapted to battle Cryptococcus infections: https://bit.ly/3hwEvFH

Researchers have copied a popular immunotherapy technique typically used in cancer treatment for fatal fungal infections. Learn more with HemaCare...

09/13/2021

If you or someone you know is open for a great opportunity, we're looking for a Business Development Executive for our Boston/Cambridge territory. Join our Team: https://bit.ly/2Xfxrqa

09/10/2021

We have the tools you need to investigate the COVID-19 immune response! Check it out: https://bit.ly/3k09r2D

HemaCare’s COVID-19 vaccinated samples include matched peripheral blood mononuclear cells (PBMCs), serum, and plasma that are collected at specific timepoints from healthy donors, with no prior COVID-19 infection, who have received a COVID-19 vaccine. These time series samples are collected prior to COVID-19 vaccination, 10-30 days after the first vaccine administration, and 10-30 days after the booster shot, when applicable.